However, in the 200 mg/kg OXC pre- and post-treated ischemia groups, the activation of Iba-1-immunoreactive microglia was significantly alleviated at 5 days after TGCI, showing that the ROD was significantly decreased by 76.1% and 62.2%, respectively, compared to that in the pre- and post- 100 mg/kg OXC treated group (Figure 5D,F,G). The gene discussed is AIF1; the disease is ischemia.